BeOne Medicines (ONC) Long-Term Debt Repayments (2018 - 2026)

BeOne Medicines (ONC) has reported Long-Term Debt Repayments for 6 consecutive years, with $17.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Long-Term Debt Repayments rose 35.51% year-over-year to $17.1 million in Q2 2026; TTM through Jun 2026 was $43.6 million, a 41.43% increase from a year earlier, with the FY2025 full-year figure at $35.7 million, up 27.29% from the prior year.
• Long-Term Debt Repayments was $17.1 million for Q2 2026 at BeOne Medicines, up from $7.6 million in the prior quarter.
• Over five years, Long-Term Debt Repayments peaked at $17.1 million in Q2 2026 and troughed at $1.5 million in Q1 2023.
• A 4-year average of $7.6 million and a median of $6.4 million in 2023 frame the typical range for Long-Term Debt Repayments.
• The widest YoY moves for Long-Term Debt Repayments: up 199.77% in 2024, down 57.92% in 2024.
• Over 4 years, Long-Term Debt Repayments stood at $5.2 million in 2023, then surged by 99.89% to $10.4 million in 2024, then surged by 39.89% to $14.6 million in 2025, then increased by 16.65% to $17.1 million in 2026.
• The last three Long-Term Debt Repayments figures came in at $17.1 million (Q2 2026), $7.6 million (Q1 2026), and $14.6 million (Q4 2025), per Business Quant data.